Gamma-aminobutyric acid type A receptor (GABAAR) benzodiazepine binding site (GABAAR BZD site)

The GABA_A receptor benzodiazepine site is a high-affinity allosteric regulatory pocket located at the interface between the alpha (specifically α1, α2, α3, or α5) and gamma (γ2) subunits of the pentameric gamma-aminobutyric acid type A (GABA_A) receptor complex [1]. As a member of the Cys-loop ligand-gated ion channel family, the GABA_A receptor is the primary mediator of fast inhibitory neurotransmission in the mammalian central nervous system [2]. When benzodiazepines or non-benzodiazepine 'Z-drugs' bind to this specific alpha/gamma interface, they induce a conformational change that increases the receptor's affinity for the endogenous neurotransmitter GABA [1, 3]. This positive allosteric modulation results in an increased frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability [2]. Consequently, this site is a critical therapeutic target for pharmacological intervention in conditions such as generalized anxiety disorder, insomnia, and various forms of epilepsy [4]. Despite their efficacy, drugs targeting this site are associated with significant clinical challenges, including the development of tolerance, physical dependence, and potential for misuse [3]. Furthermore, the lack of subunit selectivity in traditional benzodiazepines often leads to unwanted side effects like excessive sedation and cognitive impairment [1].

Other names

Benzodiazepine receptorBZD siteGABA_A receptor alpha-gamma interfaceBZ siteBenzodiazepine binding siteOmega receptor

Positive allosteric modulation (PAM) of the GABA_A receptor; binding at the alpha/gamma subunit interface increases the receptor's affinity for GABA and increases the frequency of chloride channel opening [1, 2].